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UnOBJECTIVES The authors sought to generate a synthetic extracellular volume fraction (ECV) from the relationship
between hematocrit and longitudinal relaxation rate of blood.
BACKGROUND ECV quantiﬁcation by cardiac magnetic resonance (CMR) measures diagnostically and prognostically
relevant changes in the extracellular space. Current methodologies require blood hematocrit (Hct) measurement—a
complication to easy clinical application. We hypothesized that the relationship between Hct and longitudinal relaxation
rate of blood (R1 ¼ 1/T1blood) could be calibrated and used to generate a synthetic ECV without Hct that was valid,
user-friendly, and prognostic.
METHODS Proof-of-concept: 427 subjects with a wide range of health and disease were divided into derivation
(n ¼ 214) and validation (n ¼ 213) cohorts. Histology cohort: 18 patients with severe aortic stenosis with histology
obtained during valve replacement. Outcome cohort: For comparison with external outcome data, we applied synthetic
ECV to 1,172 consecutive patients (median follow-up 1.7 years; 74 deaths). All underwent CMR scanning at 1.5-T with ECV
calculation from pre- and post-contrast T1 (blood and myocardium) and venous Hct.
RESULTS Proof-of-concept: In the derivation cohort, native R1blood and Hct showed a linear relationship (R2 ¼ 0.51;
p < 0.001), which was used to create synthetic Hct and ECV. Synthetic ECV correlated well with conventional ECV
(R2 ¼ 0.97; p < 0.001) without bias. These results were maintained in the validation cohort. Histology cohort: Synthetic
and conventional ECV both correlated well with collagen volume fraction measured from histology (R2 ¼ 0.61 and 0.69,
both p < 0.001) with no statistical difference (p ¼ 0.70). Outcome cohort: Synthetic ECV related to all-cause mortality
(hazard ratio 1.90; 95% conﬁdence interval 1.55 to 2.31; for every 5% increase in ECV). Finally, we engineered a synthetic
ECV tool, generating automatic ECV maps during image acquisition.
CONCLUSIONS Synthetic ECV provides validated noninvasive quantiﬁcation of the myocardial extracellular
space without blood sampling and is associated with cardiovascular outcomes. (J Am Coll Cardiol Img 2016;9:54–63)
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AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
CMR = cardiac magnetic
resonance
CVF = collagen volume fraction
ECM = extracellular matrix
ECV = extracellular volume
fraction
Hct = hematocrit
HHF = hospitalization for heart
failure
MOCO = motion correction
MOLLI = MOdiﬁed Look-Locker
Inversion recovery
ShMOLLI = Shortened
MOdiﬁed Look-Locker Inversion
recovery
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55I n health and disease, cardiac function is gov-erned by an intricate interplay between myocar-dial cellular and interstitial components (1).
Changes in the extracellular matrix (ECM) occur in
adverse remodeling, e.g. diffuse ﬁbrosis (2–4). Car-
diac magnetic resonance (CMR) now permits mea-
surement of this by using T1 mapping to quantify
the extracellular volume fraction (ECV) (5,6). T1 map-
ping measures the longitudinal relaxation time,
which is altered by myocardial ﬁbrosis, edema, iron
overload, and inﬁltrative diseases like amyloidosis
(7,8). After administration of a gadolinium-based
extracellular contrast agent, T1 is shortened. The
ECV is derived from the ratio of changes in signal in
myocardium and blood pre- and post-contrast and in-
volves correction for the blood hematocrit. Early data
suggests that ECV predicts mortality and major
adverse cardiac events independently and as well as
left ventricular ejection fraction excluding hypertro-
phic cardiomyopathy, amyloidosis, or congenital
heart disease (9,10). Hematocrit (Hct) measurement
is needed, which is cumbersome, introduces vari-
ability, and delays workﬂow, impeding adoption of
the method (11–13).
The longitudinal relaxivity (R1 ¼ 1/T1) of blood has
been studied since the 1980s and was found to be in a
linear relationship with blood Hct. It is determined by
the water fractions of plasma and the erythrocyte
cytoplasm, which undergo fast water exchange
(7,14–20).
We hypothesize that this relationship could be
used to estimate a synthetic Hct, permitting im-
mediate synthetic ECV calculation without blood
sampling. We formed a network of collaboration
with existing key patient cohorts to investigate
whether synthetic ECV: 1) was valid compared to
conventional ECV; 2) correlated with the gold
standard collagen volume fraction (CVF); 3) pre-
dicted outcome and 4) could be automated for in-
line point-of-care use.SEE PAGE 64METHODS
PATIENT POPULATIONS. Research was carried out
at 2 centers (Table 1): University College London Hos-
pital NHS Trust, United Kingdom (proof-of-conceptthe American Heart Association Scientist Development fund; he has acce
research purposes beyond the scope of this work. Prof. Moon is directly and in
Hospitals NIHR Biomedical Research Centre and Biomedical Research Unit a
reported that they have no relationships relevant to the contents of this pap
Manuscript received September 28, 2015; revised manuscript received Noveand histology cohorts); and UPMC CMR
Center, Pittsburgh, Pennsylvania (outcome
cohort). Study approvals were granted by local
ethics committees, and conformed to the
principles of the Helsinki Declaration. ECV
data of 2 previously published cohorts was
used to validate the synthetic ECV methodol-
ogy (histology and outcome cohorts).
Proof-of-concept of synthetic ECV: cohorts 1
(derivation) and 2 (validation). A total of n ¼ 427
subjects gave written informed consent and
were scanned between January 2012 and
October 2014. They were then randomly split
into derivation and validation subgroups
(Table 2) with equal health and disease
representation.
Normal healthy subjects (n ¼ 66, median
age 45  14 years [range 24 to 74 years], 59%
male), with no history or symptoms of cardiovascular
disease or diabetes: All had normal blood pressure
(deﬁned as <140/90 mm Hg), 12-lead electrocardio-
gram, and clinical CMR results.
Hypertrophic cardiomyopathy patients (n ¼ 68,
median age 52  14 years [range 23 to 77 years], 81%
male): All met previously described diagnostic criteria
(21). Hypertrophy was 81% asymmetrical, 9%
concentric, and 10% apical predominant.
Severe aortic stenosis (AS) patients (n¼ 123, median
age 70  10 years [range 34 to 84 years], 55% male): All
had undergone clinical evaluation and echocardiog-
raphy for diagnosis of severe AS and were listed for
surgical valve replacement.
Cardiac amyloidosis patients (n ¼ 74, median age 72
 11 years [range 38 to 85 years], 82% male): Cardiac
amyloid was only transthyretin amyloid (ATTR). This
was deﬁned by either a myocardial biopsy, or positive
bone scintigraphy. Patients underwent sequencing of
exons 2, 3, and 4 of the TTR gene. Consensus criteria
for deﬁnite cardiac involvement are pending, but not
published: deﬁnite cardiac transthyretin amyloid was
deﬁned as previously described (22,23).
Patients post-anthracycline chemotherapy for his-
tologically proven breast carcinoma at a median
follow-up of 6.4 years (n ¼ 96, median age 54 years
[range 28 to 71 years], 100% female, 100% Caucasian),
with no previous chemo- or radiotherapy or any pre-
existing cardiovascular disease or drug history.pted contrast material from Bracco Diagnostics for
directly supported by the University College London
t Barts Hospital, respectively. All other authors have
er to disclose.
mber 30, 2015, accepted November 30, 2015.
TABLE 1 Overview of Study Cohorts
Subjects Location Characteristics
Proof-of-concept n ¼ 427 London, UK Health and disease, split into derivation
and validation cohorts (Table 2).
Histology n ¼ 18 London, UK Severe aortic stenosis patients
undergoing aortic valve replacement
(with intraoperative myocardial
biopsy)
Outcome n ¼ 1,172 Pittsburgh, PA Clinical cohort referred for CMR
(Online Table S1)
CMR ¼ cardiovascular magnetic resonance.
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56HISTOLOGICAL VALIDATION OF SYNTHETIC ECV:
HISTOLOGY COHORT. Consenting (same center) se-
vere AS patients (n ¼ 18, median age 71  10 years
[range 47 to 84 years], 78% male) were scanned
between May 2011 and February 2012. All had un-
dergone clinical evaluation and echocardiography
for diagnosis before surgical aortic valve replace-
ment, and intraoperative biopsies were obtained for
histological measurement of CVF as previously
described (24).Patient Characteristics for Derivation and Validation of
Hct
Derivation
(n ¼ 214)
Validation
(n ¼ 213) p Value
107 104 0.8
60  15 60  15 0.6
1.87  0.23 1.87  0.23 0.8
lunteer 33 33
nosis 62 61
yloidosis 37 37
hic cardiomyopathy 34 34
line 48 48
l/m2 71  21 70  20 0.9
l/m2 25  14 24  13 0.5
index, g/m2 90  35 92  35 0.5
olume index, ml/m2 47  12 47  13 0.7
66  12 67  12 0.7
2/m2 14  3 14  5 0.5
crit 0.40  0.04 0.40  0.04 0.4
ne, micromol/l 79  24 78  21 0.9
ls/min/1.73 m2 80  23 78  22 0.4
Hg 110  44 108  49 0.7
m Hg 65  28 62  31 0.5
g
I ECV, % 33  10 33  11 0.9
CV, % 33  11 33  11 0.8
or mean  SD.
dy surface area; DBP ¼ diastolic blood pressure; ECV ¼ extracellular volume fraction;
xed end-diastolic volume; ESVi ¼ indexed end-systolic volume; eGFR ¼ estimated
ﬁltration rate; Hct ¼ hematocrit; LAAi ¼ indexed left atrial area; LVEF ¼ left ven-
tion fraction; MOLLI ¼ MOdiﬁed Look-Locker Inversion recovery; ShMOLLI ¼ Short-
ed Look-Locker Inversion recovery; SBP ¼ systolic blood pressure.CORRELATION OF SYNTHETIC ECV WITH OUTCOME:
OUTCOME COHORT. For external validation of syn-
thetic ECV and comparison with outcome data,
we applied the method to a large ECV outcome
cohort (25): 1,765 consecutive adult patients referred
for clinical CMR at UPMC CMR Center, Pittsburgh,
Pennsylvania (enrolled December 2009 to May 2013;
follow-up until July 2013). Inclusion criteria were
written informed consent and completion of contrast
CMR. Exclusion criteria were cardiac amyloidosis
(n ¼ 27), hypertrophic cardiomyopathy (n ¼ 133),
stress-induced cardiomyopathy (n ¼ 10), adult
congenital heart disease (n ¼ 195), inadequate image
quality (n ¼ 4), and missing follow-up (n ¼ 224). Pa-
tients with myocardial infarction were included to
maximize generalizability (ECV measured in remote
noninfarcted myocardium). The ﬁnal cohort included
1,172 patients (Table 3).
AUTOMATED INLINE ECV: SYNTHETIC ECV MAPS
“ON-THE-FLY”. An investigational prototype ECV
tool, previously developed by Kellman et al. (26,27),
was adapted to measure T1blood, calculate synthetic
Hct, and generate inline synthetic ECV maps as
DICOM images on the CMR scanner; fully automated
using coregistration and blood pool segmentation.
CMR SCANNING. All subjects underwent CMR at 1.5-T
(Magnetom Avanto, Espree, and Aera, Siemens Medi-
cal Solutions, Malvern, Pennsylvania) with 32-channel
cardiac coil arrays. Exclusion criteria were uncon-
trolled arrhythmia, impaired renal function (estimated
glomerular ﬁltration rate <30 ml/min), or contraindi-
cations to magnetic resonance imaging (e.g., implan-
ted devices). Speciﬁc details are listed in the individual
cohort descriptions. All patients underwent standard
clinical scan with late gadolinium imaging (28) with
T1 mapping before and after bolus gadolinium
contrast: for the proof-of-concept and histology co-
horts, 0.1 mmol/kg of gadoterate meglumine, (gado-
linium-DOTA, marketed as Dotarem, Guerbet S.A.,
Paris, France); for the outcome cohort, 0.2 mmol/kg
intravenous gadoteridol bolus (ProHance, Bracco
Diagnostics, Princeton, New Jersey). Post-contrast
imaging was performed at 15 to 20 min apart from
amyloid patients, where we acquired equilibrium-
contrast T1 maps (24,29). The T1 mapping sequences
used were balanced steady-state free precession–
based MOdiﬁed Look-Locker Inversion Recovery
(MOLLI) (11) variants (investigational prototypes): in
the proof-of-concept cohort, both a Shortened MOdi-
ﬁed Look-Locker Inversion recovery (ShMOLLI)
sequence and a MOLLI variant with motion correction
were used (30,31). The histological validation was
performed with ShMOLLI, whereas the outcome
TABLE 3 Clinical Characteristics of the Outcome Cohort
Demographics N ¼ 1,172
Age, yrs 56 (43–66)
Female 484 (48)
White race 1033 (88)
Black race 112 (10)
Comorbidity
Diabetes 239 (20)
Hypertension 585 (50)
Dyslipidemia 448 (38)
Atrial ﬁbrillation or ﬂutter 121 (10)
Prior coronary revascularization 217 (19)
Body mass index, kg/m2 28 (25–33)
Laboratory and CMR characteristics
Creatinine, mg/dl 0.9 (0.8–1.1)
Glomerular ﬁltration rate, ml/min/1.73 m2 89 (70–94)
Ejection fraction, % 57 (45–64)
Left ventricular mass index, g/m2 57 (46–71)
End diastolic volume index, ml/m2 82 (67–101)
End systolic volume index, ml/m2 34 (25–51)
Myocardial infarction 238 (20)
Nonischemic ﬁbrosis evident on LGE images 236 (20)
Extracellular volume fraction, % 28 (26–31)
Values are median (interquartile range) or n (%).
CMR ¼ cardiac magnetic resonance; LGE ¼ late gadolinium enhancement.
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57cohort was performed with a MOLLI with motion
correction (for sequence parameters see Supplemen-
tary material).
T1 ANALYSIS AND ECV QUANTIFICATION. A region
of interest was drawn in myocardium (in the septum
on a short-axis slice) and blood (same slice) on the pre-
contrast images and transposed to the post-contrast
images. All analysis was performed blinded. We
quantiﬁed ECM expansion with ECV deﬁned as (8):
ECV ¼ ð1 hematocritÞ $ DR1myocardium

DR1bloodpool

(where, DR1myocardium ¼ R1postcontrastmyocardium  R1precontrastmyocardium
DR1blood ¼ R1postcontrastblood R1precontrastblood
R1 ¼ 1/T1)
LABORATORY HCT VARIABILITY. Whole blood for
venous Hct was drawn in all subjects by venipuncture
and analyzed as routine clinical samples using a
Sysmex XE-2100 hematology analyzer (Sysmex, Kobe,
Japan) (32). Repeat sampling variability was tested in
44 patients who underwent 2 samples a median of 4 h
apart.
SYNTHETIC HCT DERIVATION. The longitudinal
relaxivity (R1 ¼ 1/T1) of blood has a linear relationship
with blood Hct, and is determined by the relaxivity of
the water fractions of plasma (R1P) and the erythrocyte
cytoplasm (R1RBC) (19):R1Blood ¼ R1P $ ð1  HctÞ þ R1RBC $ Hct
Rearranging gives: Hct ¼ R1P=ðR1RBC  R1PÞ þ R1Blood $
½1=ðR1RBC  R1PÞ
Simpliﬁed as: Hct ¼ Constant#1þ ðConstant#2 $ R1bloodÞ
Therefore, synthetic Hct was derived from the
linear relationship between Hct and R1blood, in turn
used to estimate a synthetic ECV and was then
compared with the conventional ECV.
HISTOLOGICAL ANALYSIS OF CVF. Histological
quantiﬁcation of the extracellular space was per-
formed by measuring the CVF as previously described
(24). In summary, an intraoperative deep myocardial
biopsy (Tru-Cut–type biopsy) was taken from the
basal left ventricular septum, stained with Picrosirius
red, photographed at high-power magniﬁcation
(200 mm), and CVF (%) automatically quantiﬁed
over an average of 12 high-power ﬁelds with a
purpose-written macro in ImageJ version 1.43, 2009
(National Institutes of Health, Bethesda, Maryland).
All samples were analyzed blinded to other ﬁndings.
STATISTICAL ANALYSIS. Analyses were performed
using SAS version 9.3 (Cary, North Carolina) and SPSS
version 22 (Chicago, Illinois). All data are presented
as mean  SD for individuals or measurements as
indicated. Differences were assessed using unpaired
Student t tests to simulate independent group com-
parisons. Statistical tests were 2-sided. Signiﬁcance
was quoted when probability was <0.05 divided by
the number of simultaneous comparisons in the
relevant analysis (Bonferroni correction). Agreement
between conventional and synthetic ECV was
analyzed using the Bland-Altman method. The sig-
niﬁcance of the difference between 2 correlation co-
efﬁcients was tested using the Fisher r-to-z
transformation. Survival analyses examined: time to
the ﬁrst hospitalization for heart failure (HHF) after
CMR, time to death, and time to either HHF or death.
First HHF included any HHF event after CMR, and
required physician documentation of: 1) symptoms
and physical signs consistent with HF; 2) supporting
clinical ﬁndings; or 3) therapy for HF. Vital status was
ascertained by Social Security Death Index queries
and medical record review (conﬁrmed by 2 blinded
investigators, E.B.S. and T.C.W.). Mortality was right
censored for the ﬁrst HHF after CMR analysis. The
log-rank test with ECV (categorized arbitrarily in 5%
increments) and Cox regression (ECV expressed as a
continuous variable) examined associations between
ECV and outcomes (more in the Online Appendix).
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58RESULTS
PROOF-OF-CONCEPT: DERIVATION AND VALIDA-
TION COHORTS. The proof-of-concept cohort was
divided randomly into a derivation (n ¼ 214) and a
validation (n ¼ 213) cohort (Table 2). In the derivation
cohort, there was a broad range of Hct (40.3  3.7%;
range 32% to 51%) and native T1blood (ShMOLLI T1blood
1,549  80 ms; range 1,261 to 1,823 ms; MOLLI T1blood
1,649  83 ms; range 1,441 to 1,898 ms). The regres-
sion line between hematocrit and R1blood (1/T1blood)
was linear with R2 ¼ 0.51, p < 0.001; and 0.45,
p < 0.001; for MOLLI and ShMOLLI, respectively
(Figure 1). The regression equations were:
Synthetic HctMOLLI ¼ (866.0 $ [1/T1blood])  0.1232
Synthetic HctShMOLLI ¼ (727.1 $ [1/T1blood])  0.0675
where Hct is hematocrit (0 to 1) and R1blood¼ (1/T1blood)
in milliseconds.
Using these curve-ﬁts in the validation cohort,
synthetic and conventional ECV were highly corre-
lated (R2 ¼ 0.97; p < 0.001, both mapping techniques)
with a 2.8% SD of differences and minimal bias on
Bland-Altman analysis for ﬁbrosis quantiﬁcation and
a slightly higher SD in difference of 5% in extracel-
lular expansion due to amyloidosis (Figure 2).
Synthetic and conventional ECV correlated equally
with clinical markers of disease severity (Online
Table S1).FIGURE 1 Derivation Cohort: Correlation R1blood Versus Hct (MOLLI
The proof-of-concept cohort was divided randomly into a derivation (n ¼
hematocrit and pre-contrast R1blood was linear with R
2 ¼ 0.51, p < 0.00
regression equations as given in the graphs. Hct ¼ hematocrit; MOLLI ¼
MOdiﬁed Look-Locker Inversion recovery.TEST-RETEST VARIABILITY. Bland-Altman compari-
son of laboratory Hct versus synthetic Hct in the
validation cohort revealed a variability of 14%,
R2 ¼ 0.44. To understand the sources of variability
attributable to laboratory Hct and synthetic Hct
(i.e., T1blood), test/retest was performed. Test/retest
variability of laboratory Hct was higher than expected
(n ¼ 44, variability 10% with Hct/Hct R2 ¼ 0.86)
(Online Figure S1), where test/retest for T1blood (and
by inference, synthetic Hct) in healthy volunteers was
low for MOLLI (n ¼ 20, variability 0.02%, R2 ¼ 0.95)
(Online Figure S2) and ShMOLLI (n ¼ 20, variability
0.012%, R2 ¼ 0.94). Interobserver reproducibility
for T1blood was also excellent (intraclass correlation
coefﬁcient 0.994, 95% CI: 0.984 to 0.998).
HISTOLOGY COHORT. The mean histological CVF of
the 18 biopsies was 17  8% (range 5% to 40%). Syn-
thetic and conventional ECV both correlated well
with collagen volume fraction (R2 ¼ 0.61, p < 0.001 vs.
R2 ¼ 0.69, p < 0.001) (Figure 3) and did not differ
statistically (p ¼ 0.70).
OUTCOME COHORT. Baseline characteristics are
presented in Table 3. The U.K. derivation resulted in a
2% bias in synthetic ECV; therefore, a local synthetic
Hct calibration was obtained (Online Figures S3, S4,
and S6). In the outcome cohort, conventional and
synthetic ECV had similar ranges (16.6% to 47.8% and
16.2% to 50.9%, respectively) with excellent correla-
tion (R2 ¼ 0.82, p < 0.001) (Online Figure S5) and no
signiﬁcant bias. Over a median of 1.7 yearsand ShMOLLI)
214) and a validation (n ¼ 213) cohorts. The regression line between
1, and R2 ¼ 0.45, p < 0.001, for MOLLI (A) and ShMOLLI (B) with
MOdiﬁed Look-Locker Inversion recovery; ShMOLLI ¼ Shortened
FIGURE 3 Histology Cohort: Conventional ECV and Synthetic ECV Versus CVF
The mean histological collagen volume fraction (CVF) of the 18 biopsies was 17  8%
(range 5% to 40%). The correlation with histology for synthetic extracellular volume
fraction (ECV) was slightly lower than the conventional ECV (R2 ¼ 0.61, p < 0.0.01 vs.
R2 ¼ 0.69, p < 0.001) but did not differ statistically (p ¼ 0.70).
FIGURE 2 Validation Cohort: Conventional Versus Synthetic ECV
Using these curve-ﬁts in the validation cohort, synthetic and conventional extracellular volume fraction (ECV) were highly correlated
(R2 ¼ 0.97; p < 0.001, both mapping techniques) with a 2.8% SD of differences and minimal bias on Bland-Altman analysis for ﬁbrosis
quantiﬁcation and a slightly higher SD in difference of 5% in extracellular expansion due to amyloidosis.
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59(interquartile range: 1.0 to 2.4 years), there were 55
HHF events and 74 deaths after the baseline CMR
scan among 111 individuals experiencing adverse
events in the n ¼ 1,172 cohort (18 individuals experi-
encing HHF subsequently died). Synthetic and con-
ventional ECV were associated with adverse events
with a graded response, where higher ECV was asso-
ciated with higher event rates (Figure 4). Conven-
tional and synthetic ECV were comparable to the
ejection fraction in their univariable association with
HHF, but ECV (conventional and synthetic) was bet-
ter than the ejection fraction for mortality (Table 4).
AUTOMATED INLINE SYNTHETIC ECV COHORT:
REAL-WORLD APPLICATION. A module was created
to generate automatic synthetic ECV maps inline
(“on-the-ﬂy”) as post-contrast T1 maps are acquired
(Figure 5, Online Video 1). The additional processing
time is <1 s per slice for ﬁnding paired pre-contrast T1
mapping data, performing image coregistration, and
generating the blood mask and synthetic ECV map.
The user is able to analyze images immediately by
drawing regions of interest on the scanner console,
where pixel values represent percentage ECV.
DISCUSSION
CMR extracellular volume quantiﬁcation is a prom-
ising imaging biomarker (33–35), but development
and clinical uptake have been slowed by the necessity
of venous blood sampling, analysis, and then ofﬂine
calculation. We implemented a simpler, synthetic
ECV measured using hematocrit estimated frompre-contrast blood T1. Synthetic ECV performed
well: it is highly correlated to conventional ECV, and
has a similar relationship to the histologic gold
standard CVF, other cardiac parameters, and predicts
outcome similarly, even at a different center. The
implementation here as an inline tool on a clinical
CMR scanner would be an aid to clinical
TABLE 4 Convention
Univariable Associatio
Outcome
U
HHF (n ¼ 55) Conv
Synt
LVEF
Death (n ¼ 74) Conv
Synt
LVEF
HHF or death
(n ¼ 111)
Conv
Synt
LVEF
ECV ¼ extracellular volum
fraction.
FIGURE 4 Outcome Cohort: Kaplan-Meier Plot (Death and HHF) for ECV
1.0
0.8
0.6
0.4
0.2
0.0Pr
ob
ab
ili
ty
 o
f H
HF
 o
r D
ea
th
Years after CMR
Conventional ECV
0
1 571 529 440 329 205 112 38 1
2 310 277 241 182 113 77 27 0
3 77 61 51 32 23 11 6 0
4 17 10 8 8 7 5 2 0
5 197 188 141 111 80 42 12 0
1 2 3
Log rank = 92
p < 0.0001
1.0
0.8
0.6
0.4
0.2
0.0
Years after CMR
Synthetic ECV
0
1 615 574 474 355 221 116 39 0
2 291 259 226 167 99 65 25 0
3 67 52 41 31 23 16 7 0
4 14 7 6 6 6 3 2 0
5 185 173 134 103 79 47 12 1
1 2 3
Log rank = 94
p < 0.0001
40% ≤ ECV 35% ≤ ECV < 40% 30% ≤ ECV < 35% 25% ≤ ECV < 30% ECV < 25%
Among 1,172 individuals, both conventional and synthetic myocardial extracellular volume fraction (ECV) were signiﬁcantly associated with increased risks of hospi-
talization for heart failure (HHF) or death (n ¼ 111) following cardiac magnetic resonance (CMR) scanning.
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60workﬂow, providing automated immediate point-of-
care results.
The technique arose out of need and the observa-
tion that pre-contrast blood T1 is considerably deter-
mined by hematocrit (pre-contrast blood T1 increases
with anemia). Indeed, the linear relationship between
Hct and R1blood (1/T1blood) has been abundantly
described (7,14–20), and therefore, R1blood was
used for curve ﬁtting. Beyond mathematical deriva-
tion, we describe 1/T1blood because it is more intuitive
for the CMR clinicians and easier to sell to the CMR
community. This is analogous to the T2* ﬁeld thatal and Synthetic ECV and LVEF Were Comparable in Their
n With HHF, Mortality, or Combined
nivariable Cox Regression
Model Covariate
Hazard Ratio
(95% CI) Chi-Square p Value
entional ECV (5% increase) 2.41 (1.93–3.02) 59.6 <0.001
hetic ECV (5% increase) 2.30 (1.87–2.81) 64.5 <0.001
(5% decrease) 1.33 (1.23–1.43) 54.3 <0.001
entional ECV (5% increase) 2.13 (1.74–2.61) 53.4 <0.001
hetic ECV (5% increase) 1.90 (1.55–2.31) 39.8 <0.001
(5% decrease) 1.21 (1.16–1.29) 32.0 <0.001
entional ECV (5% increase) 2.25 (1.91–2.64) 96.0 <0.001
hetic ECV (5% increase) 2.06 (1.77–2.40) 89.2 <0.001
(5% decrease) 1.26 (1.19–1.33) 71.7 <0.001
e fraction; HHF ¼ hospitalization for heart failure; LVEF ¼ left ventricular ejectionuses T2* rather than the R2*. Although the correlation
of peripheral Hct and ventricular cavity pre-contrast
R1blood is only moderate (other inﬂuences are dis-
cussed in the following text), synthetic ECV perfor-
mance is good, which we believe is in part due to
considerable error in standard laboratory Hct when
taken as a routine clinical test, and also because the
ECV has other dependencies that make it robust
(6,9,10,36). It may be that an overlooked weakness
has been the variability of Hct measurement (37).
Here, the correlation of 2 Hct samples on the same
day to a clinical service (located in a different build-
ing so with potential settling and re-suspension of
red cells during transport) was only a R2 of 0.86—
potentially a greater source of inaccuracy than the
differences contested between T1 mapping ap-
proaches (30,38).
ECV is gaining recognition as a potentially key
biomarker of ECM expansion and has been called
“noninvasive” or “virtual biopsy” (39). The near-
exponential increase of evidence for the role of T1
mapping and ECV quantiﬁcation for myocardial tissue
characterization calls for the routine clinical use
beyond late gadolinium enhancement (Novel Markers
of Prognosis in Hypertrophic Cardiomyopathy;
[HCMR Study]; NCT01915615). Separate analysis of
pre- and post-contrast images is cumbersome.
Although implementation of automated ECV map
tools is simplifying this (40), Hct measure is
FIGURE 5 Automatic Synthetic ECV Tool: ECV Mapping “on-the-Fly”
An automated inline synthetic extracellular volume fraction (ECV) tool was implemented as an investigational prototype to produce a fast and fully automated approach
for generating pixel-wise synthetic ECV maps (Online Video 1).
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61burdensome in busy departments, is a source of user
error, and introduces reporting delay. An inline syn-
thetic ECV tool would reduce the barriers to clinical
use of ECV and potentially increase quality as review
is immediate.
STUDY LIMITATIONS. Although this study was not a
multicenter study, following validation and deriva-
tion in a single center, we then tested outcome in a
separate center. The T1 mapping methods varied
across parts of experiments (in line with rapid de-
velopments within the T1 mapping ﬁeld), and further
comparisons are required. As for any other non-
contrast mapping parameter, synthetic Hct requires
local calibration, unless T1 mapping sequence, CMR
scanner, and Hct machine are identical. Other sources
that affect the relaxation rate of blood such as ﬂow,
oxygen content, body temperature, and contributions
from other biological variables need further investi-
gation (e.g., red cell shape and size, other macro-
molecules, and even added substances, e.g.,
intravenous iron or other paramagnetic substances)
(7,14,17,18,41–43). In iron overload, particularly in
thalassemia patients, the R1/Hct relationship breaks
down (unpublished data), which may to be due to
iron-chelator complexes. Finally, there are additional
inﬂuences on measured T1blood (e.g., residual heart
rate dependence with some sequences, where
measured T1blood decreases with increasing heart
rate). The range of diseases studied was notexhaustive, and extreme patients (e.g., very anemic)
are not well represented. Variability of repeat syn-
thetic ECV was not tested due to the requirement to
use gadolinium contrast to assess this, but variability
of T1blood, and thereby synthetic Hct, was low across
repeated scans, making it a suitable tool for clinical
trials (44). The synthetic ECV approach highlights Hct
measurement issues that may be easily solved
without resorting to new approaches, improving the
conventional ECV method.
CONCLUSIONS
The CMR biomarker ECV is promising as a measure of
the myocardial interstitial space and can be simpliﬁed
and automated by using a synthetic Hct. Synthetic
ECV is validated in health and disease, against his-
tology, across centers, and predicts outcome as well
as the conventional ECV. Automated synthetic ECV
measures can be implemented inline on the CMR
scanner with test performances approaching that of
conventional ECV measurement—a signiﬁcant work-
ﬂow improvement bringing ECV closer to routine
clinical practice.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: ECV is a
promising imaging biomarker, but requires venous blood
sampling for analysis and ofﬂine calculation. A simpler,
synthetic ECV can be measured using hematocrit esti-
mated from the longitudinal relaxation rate of blood.
Synthetic ECV is highly correlated to conventional ECV,
validated against histology and predicts outcome simi-
larly, even at a different center. Implementation of an
automatic inline tool on a clinical CMR scanner can aid
clinical workﬂow, providing immediate point-of-care
results.
TRANSLATIONAL OUTLOOK: The synthetic ECV
approach highlights hematocrit measurement issues that
may be easily solved without resorting to new ap-
proaches, improving the conventional ECV method. Syn-
thetic hematocrit requires local calibration, unless T1
mapping sequence, CMR scanner and hematocrit machine
are identical. Other sources that affect the relaxation rate
of blood such as ﬂow, oxygen content, body temperature,
and contributions from other biological variables need
further investigation.
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